Amgen Inc. (NASDAQ:AMGN) Shares Bought by ST Germain D J Co. Inc.

ST Germain D J Co. Inc. raised its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 82,348 shares of the medical research company's stock after buying an additional 4,042 shares during the period. Amgen comprises about 1.0% of ST Germain D J Co. Inc.'s holdings, making the stock its 28th largest holding. ST Germain D J Co. Inc.'s holdings in Amgen were worth $21,463,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Capital Performance Advisors LLP purchased a new position in Amgen during the 3rd quarter valued at about $25,000. Strategic Financial Concepts LLC acquired a new stake in shares of Amgen during the second quarter worth about $26,000. Legacy Investment Solutions LLC purchased a new position in shares of Amgen in the third quarter valued at approximately $29,000. Hershey Financial Advisers LLC acquired a new position in shares of Amgen in the second quarter valued at approximately $30,000. Finally, Matrix Trust Co purchased a new stake in Amgen during the 3rd quarter worth approximately $36,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Citigroup decreased their price target on shares of Amgen from $335.00 to $310.00 in a research report on Wednesday, November 27th. Jefferies Financial Group reiterated a "buy" rating and issued a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Sanford C. Bernstein initiated coverage on Amgen in a report on Thursday, October 17th. They set an "outperform" rating and a $380.00 price target on the stock. Truist Financial decreased their price objective on Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a research note on Wednesday. Finally, Robert W. Baird restated an "underperform" rating and set a $215.00 target price on shares of Amgen in a research note on Wednesday, September 25th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $314.91.

Amgen Stock Performance

Shares of Amgen stock traded down $1.98 during trading on Friday, reaching $262.23. The company's stock had a trading volume of 2,721,781 shares, compared to its average volume of 3,053,942. The company has a 50-day moving average price of $279.10 and a two-hundred day moving average price of $308.76. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm has a market cap of $140.96 billion, a PE ratio of 33.58, a P/E/G ratio of 2.91 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts' consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the business posted $4.96 earnings per share. Amgen's quarterly revenue was up 23.2% on a year-over-year basis. On average, analysts forecast that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.63%. This is a boost from Amgen's previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen's dividend payout ratio (DPR) is presently 121.90%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.